BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Cited by (1,007)

Items 101–200 of 1,007

1. Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers
   Yoel Angel, Avishay Spitzer, Oryan Henig, Esther Saiag, Eli Sprecher, Hagit Padova, Ronen Ben‐Ami · 2021 · JAMA
2. Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study
   Matthias B. Moor, Franziska Suter‐Riniker, Michael Peter Horn, Daniel Aeberli, Jennifer Amsler, Burkhard Möller, Linet Muthoni Njue, Cesare Medri, Anne Angelillo‐Scherrer, Luca Borradori et al. · 2021 · The Lancet Rheumatology
3. Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study
   Benaya Rozen‐Zvi, Dafna Yahav, Timna Agur, Boris V. Zingerman, Haim Ben‐Zvi, Alaa Atamna, Noam Tau, Tiki Mashraki, Eviatar Nesher, Ruth Rahamimov · 2021 · Clinical Microbiology and Infection
4. mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron
   Matthew Gagné, Juan I. Moliva, Kathryn E. Foulds, Shayne F. Andrew, Barbara J. Flynn, Anne P. Werner, Danielle A. Wagner, I‐Ting Teng, Bob C. Lin, Christopher A. Moore et al. · 2022 · Cell
5. The Global Epidemic of the SARS-CoV-2 Delta Variant, Key Spike Mutations and Immune Escape
   Dandan Tian, Yanhong Sun, Jianming Zhou, Qing Ye · 2021 · Frontiers in Immunology
6. The Effectiveness of the Two-Dose BNT162b2 Vaccine: Analysis of Real-World Data
   Chodick, Gabriel, Tene, Lilac, Rotem, Ran S, Patalon, Tal, Gazit, Sivan, Ben-Tov, Amir, Weil, Clara, Goldshtein, Inbal, Twig, Gilad, Cohen, Dani et al. · 2022 · Clinical Infectious Diseases
7. The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines
   Gary R. McLean, Jeremy P. Kamil, Benhur Lee, Penny L. Moore, Thomas Friedrich Schulz, Alexander Muik, Uğur Şahin, Özlem Türeci, Shanti Pather · 2022 · mBio
8. Exponential growth, high prevalence of SARS-CoV-2, and vaccine effectiveness associated with the Delta variant
   Paul Elliott, David Haw, Haowei Wang, Oliver D. Eales, Caroline E. Walters, Kylie E. C. Ainslie, Christina Joanne Atchison, Claudio Fronterrè, Peter John Diggle, Andrew J. Page et al. · 2021 · Science
9. Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2
   Israelow, Benjamin, Mao, Tianyang, Klein, Jonathan, Song, Eric, Menasche, Bridget, Omer, Saad B., Iwasaki, Akiko · 2021 · Science Immunology
10. Interim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and Moderna COVID-19 Vaccines Among Health Care Personnel — 33 U.S. Sites, January–March 2021
    Tamara Pilishvili, Katherine E. Fleming-Dutra, Jennifer Loo Farrar, Ryan Gierke, Nicholas M. Mohr, David A. Talan, Anusha Krishnadasan, Karisa K. Harland, Howard A Smithline, Peter Chuanyi Hou et al. · 2021 · MMWR Morbidity and Mortality Weekly Report
11. Early T cell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onset
    Shirin Kalimuddin, Christine Y. L. Tham, Martin Qui, Ruklanthi de Alwis, Jean Xiang Ying Sim, Joey Ming Er Lim, Hwee-Cheng Tan, Ayesa Syenina, Summer Li-Xin Zhang, Nina Le Bert et al. · 2021 · Med
12. Target Trial Emulation to Improve Causal Inference from Observational Data: What, Why, and How?
    Edouard L. Fu · 2023 · Journal of the American Society of Nephrology
13. Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2
    Israelow, Benjamin, Mao, Tianyang, Klein, Jonathan, Song, Eric, Menasche, Bridget, Omer, Saad B., Iwasaki, Akiko · 2021
14. COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies
    Renuka Raman, Krishna J. Patel, Kishu Ranjan · 2021 · Biomolecules
15. FDA-authorized mRNA COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system
    Colin Pawlowski, Patrick J. Lenehan, Arjun Puranik, Vineet Agarwal, AJ Venkatakrishnan, Michiel J.M. Niesen, John Charles O’Horo, Abinash Virk, Melanie D. Swift, Andrew D. Badley et al. · 2021 · Med
16. Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After Immunization
    Gabriel Chodick, Lilac Tene, Tal Patalon, Sivan Gazit, Amir Ben‐Tov, Dani Cohen, Khitam Muhsen · 2021 · JAMA Network Open
17. Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry
    Pedro Machado, Saskia Lawson‐Tovey, Anja Strangfeld, Elsa F Mateus, Kimme Leanne Hyrich, Laure Gossec, Loreto Carmona, Ana Rodrigues, Bernd Raffeiner, Catia Duarte et al. · 2021 · Annals of the Rheumatic Diseases
18. Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA Vaccine BNT162b2 In Vitro in Human Liver Cell Line
    Markus Aldén, Francisko Olofsson Falla, Daowei Yang, Mohammad Barghouth, Cheng Luan, Magnus Rasmussen, Yang Z. De Marinis · 2022 · Current Issues in Molecular Biology
19. Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity
    David Hagin, Tal Freund, Michal Navon, Tami Halperin, Dikla Adir, Rotem Marom, Inbar Levi, Shira Benor, Yifat Alcalay, Natalia Tarnovitski Freund · 2021 · Journal of Allergy and Clinical Immunology
20. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Naturally Acquired Immunity versus Vaccine-induced Immunity, Reinfections versus Breakthrough Infections: A Retrospective Cohort Study
    Gazit, Sivan, Shlezinger, Roei, Perez, Galit, Lotan, Roni, Peretz, Asaf, Ben-Tov, Amir, Herzel, Esma, Alapi, Hillel, Cohen, Dani, Muhsen, Khitam et al. · 2022 · Clinical Infectious Diseases
21. Recent Advancement in mRNA Vaccine Development and Applications
    Nojoud AL Fayez, Majed Saeed Nassar, Abdullah Awad Alshehri, Meshal K. Alnefaie, Fahad A. Almughem, Bayan Y. Alshehri, Abdullah O. Alawad, Essam A. Tawfik · 2023 · Pharmaceutics
22. COVID-19 in long-term care
    Eileen Rocard, Paola Sillitti, Ana Llena Nozal · 2021 · OECD health working papers
23. Modelling of COVID-19 vaccination strategies and herd immunity, in scenarios of limited and full vaccine supply in NSW, Australia
    Chandini Raina MacIntyre, Valentina Costantino, Mallory J. Trent · 2021 · Vaccine
24. Immunity to SARS‐CoV‐2 induced by infection or vaccination
    Xaquín Castro Dopico, Sebastian Ols, Karin Loré, Gunilla B. Karlsson Hedestam · 2021 · Journal of Internal Medicine
25. Applying lessons learned from nanomedicines to understand rare hypersensitivity reactions to mRNA-based SARS-CoV-2 vaccines
    János Szebeni, Gert Storm, Julia Y. Ljubimova, Mariana Castells, Elizabeth Jane Phillips, Keren Turjeman, Yechezkel Barenholz, Daan J.A. Crommelin, Marina A. Dobrovolskaia · 2022 · Nature Nanotechnology
26. T-Cell and Antibody Responses to First BNT162b2 Vaccine Dose in Previously SARS-CoV-2-Infected and Infection-Naive UK Healthcare Workers: A Multicentre, Prospective, Observational Cohort Study
    Adrienn Angyal, Stéphanie Longet, Shona C. Moore, Rebecca Payne, Adam C. Harding, Tom Tipton, Patpong Rongkard, Mohammad Ali, Luisa M. Hering, Naomi Meardon et al. · 2021 · The Lancet Microbe
27. Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response amongst individuals in clinical risk groups
    Heather Whitaker, Ruby S. M. Tsang, Rachel C. Byford, Nick J Andrews, Julian Sherlock, Praveen Sebastian Pillai, John Williams, Elizabeth Button, Helen Campbell, Mary Sinnathamby et al. · 2022 · Journal of Infection
28. Mechanisms of Immunothrombosis in Vaccine-Induced Thrombotic Thrombocytopenia (VITT) Compared to Natural SARS-CoV-2 Infection
    Dennis McGonagle, Gabriele De Marco, Charles Bridgewood · 2021 · Journal of Autoimmunity
29. Cross-sectional analysis of COVID-19 vaccine intention, perceptions and hesitancy across Latin America and the Caribbean
    Diego Urrunaga‐Pastor, Guido Bendezú-Quispe, Percy Herrera‐Añazco, Angela Uyen‐Cateriano, Carlos Jesus Toro-Huamanchumo, Alfonso Javier Rodriguez-Morales, Adrián Vladimir Hernández, Vicente Aleixandre Benites-Zapata · 2021 · Travel Medicine and Infectious Disease
30. BNT162b2 COVID ‐19 vaccine is significantly less effective in patients with hematologic malignancies
    Katrin Herzog Tzarfati, Odit Gutwein, Arie Apel, Naomi Rahimi‐Levene, Maya Sadovnik, Lotem Harel, Patricia Benveniste‐Levkovitz, Adina Bar Chaim, Maya Koren‐Michowitz · 2021 · American Journal of Hematology
31. Myocarditis Following COVID-19 Vaccine: Incidence, Presentation, Diagnosis, Pathophysiology, Therapy, and Outcomes Put Into Perspective. A Clinical Consensus Document Supported by the Heart Failure Association of the European Society of Cardiology (ESC) and the ESC Working Group on Myocardial and Pericardial Diseases
    Heidecker, Bettina, Dagan, Noa, Balicer, Ran, Eriksson, Urs, Rosano, Giuseppe, Coats, Andrew, Tschöpe, Carsten, Kelle, Sebastian, Poland, Gregory A., Frustaci, Andrea et al. · 2022 · European Journal of Heart Failure
32. Association of SARS-CoV-2 Vaccination During Pregnancy With Pregnancy Outcomes
    Maria Christine Magnus, Anne K. Örtqvist, Elisabeth Dahlqwist, Rickard Ljung, Fredrik Skår, Laura Oakley, Ferenc Macsali, Björn Pasternak, Håkon Kristian Gjessing, Siri E. Håberg et al. · 2022 · JAMA
33. Short‐term outcome of pregnant women vaccinated with BNT162b2 mRNA COVID ‐19 vaccine
    Shiran Bookstein-Peretz, N. Regev, Lia Novick, Michal Nachshol, E. Goffer, Alon Ben‐David, Keren Asraf, Ram Doolman, Einav Gal Levin, Gili Regev‐Yochay et al. · 2021 · Ultrasound in Obstetrics and Gynecology
34. Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine
    Patalon, Tal, Saciuk, Yaki, Peretz, Asaf, Perez, Galit, Lurie, Yoav, Maor, Yasmin, Gazit, Sivan · 2022 · Nature Communications
35. Optimizing vaccine allocation for COVID-19 vaccines shows the potential role of single-dose vaccination
    Laura Matrajt, Julia Eaton, Tiffany Leung, Dobromir Dimitrov, Joshua Tisdell Schiffer, David A. Swan, Holly Janes · 2021 · Nature Communications
36. Prenatal maternal COVID-19 vaccination and pregnancy outcomes
    Tamar Wainstock, Israel Yoles, Ruslan Sergienko, Eyal Sheiner · 2021 · Vaccine
37. Evaluation of COVID-19 vaccination strategies with a delayed second dose
    Seyed M. Moghadas, THOMAS NOGUEIRA VILCHES, Kevin Zhang, Shokoofeh Nourbakhsh, Pratha Sah, Meagan C. Fitzpatrick, Alison P. Galvani · 2021 · PLoS Biology
38. Psychological Determinants of COVID-19 Vaccine Acceptance among Healthcare Workers in Kuwait: A Cross-Sectional Study Using the 5C and Vaccine Conspiracy Beliefs Scales
    Mariam Alsanafi, Malik Sallam · 2021 · Vaccines
39. Emerging SARS-CoV-2 Variants: A Review of Its Mutations, Its Implications and Vaccine Efficacy
    Sindhu Ramesh, Manoj Govindarajulu, Rachel S. Parise, Logan T. Neel, Tharanath Shankar, Shriya Patel, Payton Lowery, Forrest Smith, Muralikrishnan Dhanasekaran, Timothy Moore · 2021 · Vaccines
40. Assessing Acceptability of COVID-19 Vaccine Booster Dose among Adult Americans: A Cross-Sectional Study
    Tesfaye Yadete, Kavita Batra, Dale M. Netski, Sabrina Antonio, Michael J. Patros, Johan Christiaan Bester · 2021 · Vaccines
41. Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel
    Prunas, Ottavia, Warren, Joshua L., Crawford, Forrest W., Gazit, Sivan, Patalon, Tal, Weinberger, Daniel M., Pitzer, Virginia E. · 2022 · Science
42. Extended interval BNT162b2 vaccination enhances peak antibody generation
    Helen Parry, Rachel K. Bruton, Christine Stephens, Christopher Bentley, Kevin Edward Brown, Gayatri Amirthalingam, Bassam Hallis, Ashley David Otter, Jianmin Zuo, Paul A. H. Moss · 2022 · npj Vaccines
43. Venovenous extracorporeal membrane oxygenation in patients with acute covid-19 associated respiratory failure: comparative effectiveness study
    Martin Urner, Adrian Gerard Barnett, Gianluigi Li Bassi, Daniel Brodie, Heidi J. Dalton, Niall D. Ferguson, Silver Heinsar, Carol Lynette Hodgson, Giles John Peek, Kiran Shekar et al. · 2022 · BMJ
44. Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years
    2022
45. Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccines for Preventing Coronavirus Disease 2019 Hospitalizations in the United States
    Mark W. Tenforde, Manish M. Patel, Adit A. Ginde, David J. Douin, H. Keipp Talbot, Jonathan Dale Casey, Nicholas M. Mohr, Anne E. Zepeski, Manjusha Gaglani, Tresa McNeal et al. · 2021 · Clinical Infectious Diseases
46. Hospitalisation among vaccine breakthrough COVID-19 infections
    Prerak V. Juthani, Akash Kumar Gupta, Kelly A. Borges, Christina C. Price, Alfred Ian Lee, Christine H. J. Won, Hyung J. Chun · 2021 · The Lancet Infectious Diseases
47. Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer
    Goshen-Lago, Tal, Waldhorn, Ithai, Holland, Roy, Szwarcwort-Cohen, Moran, Reiner-Benaim, Anat, Shachor-Meyouhas, Yael, Hussein, Khetam, Fahoum, Liana, Baruch, Mali, Peer, Avivit et al. · 2021 · JAMA Oncology
48. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study
    Denis Sauré, Miguel O’Ryan, Juan Pablo Torres, Marcela Zuniga, Emilio Santelices, Leonardo J. Basso · 2021 · The Lancet Infectious Diseases
49. Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study
    Peter Nordström, Marcel Ballin, Anna Nordström · 2021 · The Lancet Regional Health - Europe
50. Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization
    Minal K. Patel, Isabel Bergeri, Joseph Bresee, Benjamin John Cowling, Natasha Sarah Crowcroft, Kamal Fahmy, Siddhivinayak S. Hirve, Gagandeep Kang, Mark A. Katz, Claudio Franco Lanata et al. · 2021 · Vaccine
51. Waning Effectiveness of the Third Dose of the BNT162b2 mRNA COVID-19 Vaccine
    Patalon, Tal, Saciuk, Yaki, Peretz, Asaf, Perez, Galit, Lurie, Yoav, Maor, Yasmin, Gazit, Sivan · 2022
52. Frequency of positive anti-PF4/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2
    Thomas Thiele, Lena Ulm, Silva Holtfreter, Linda Schönborn, Sven‐Olaf Kuhn, Christian Scheer, Theodore Earl Warkentin, Barbara M. Bröker, Karsten Becker, Konstanze Aurich et al. · 2021 · Blood
53. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infectivity by Viral Load, S Gene Variants and Demographic Factors, and the Utility of Lateral Flow Devices to Prevent Transmission
    Lennard Y. W. Lee, Stefan Rozmanowski, Matthew Pang, André Charlett, Charlotte S Anderson, Gareth J Hughes, Matthew Barnard, Leon Peto, Richard Vipond, Alex Sienkiewicz et al. · 2021 · Clinical Infectious Diseases
54. Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel
    Yaniv Lustig, Neta S. Zuckerman, Ital Nemet, Nofar Atari, Limor Kliker, Gili Regev‐Yochay, Einav Sapir, Orna Mor, Sharon Alroy‐Preis, Ella Mendelson et al. · 2021 · Eurosurveillance
55. Addressing vaccine hesitancy and access barriers to achieve persistent progress in Israel’s COVID-19 vaccination program
    Bruce Rosen, Ruth Waitzberg, Avi Israeli, Michael Hartal, Nadav Davidovitch · 2021 · Israel Journal of Health Policy Research
56. Odds of Testing Positive for SARS-CoV-2 Following Receipt of 3 vs 2 Doses of the BNT162b2 mRNA Vaccine
    Patalon, Tal, Gazit, Sivan, Pitzer, Virginia E., Prunas, Ottavia, Warren, Joshua L., Weinberger, Daniel M. · 2022 · JAMA Internal Medicine
57. Vaccination against COVID-19: insight from arterial and venous thrombosis occurrence using data from VigiBase
    David M. Smadja, Qun‐Ying Yue, Richard Chocron, Olivier Sanchez, Agnés Lillo‐Le Louët · 2021 · European Respiratory Journal
58. Risk of hospitalisation associated with infection with SARS-CoV-2 lineage B.1.1.7 in Denmark: an observational cohort study
    Peter Bager, Jan Wohlfahrt, Jannik Fonager, Morten Rasmussen, Mads Albertsen, Thomas Yssing Michaelsen, Camilla Holten Møller, Steen Ethelberg, Rebecca A. Legarth, Mia Sarah Fischer Button et al. · 2021 · The Lancet Infectious Diseases
59. First-dose mRNA vaccination is sufficient to reactivate immunological memory to SARS-CoV-2 in subjects who have recovered from COVID-19
    Mazzoni, Alessio, Di Lauria, Nicoletta, Maggi, Laura, Salvati, Lorenzo, Vanni, Anna, Capone, Manuela, Lamacchia, Giulia, Mantengoli, Elisabetta, Spinicci, Michele, Zammarchi, Lorenzo et al. · 2021 · Journal of Clinical Investigation
60. Two Years into the COVID-19 Pandemic: Lessons Learned
    Severino Jefferson Ribeiro da Silva, Jéssica Catarine Frutuoso do Nascimento, Renata Pessôa Germano Mendes, Klarissa Miranda Guarines, Caroline Targino Alves da Silva, Poliana Gomes da Silva, Jurandy Júnior Ferraz de Magalhães, Justin R. J. Vigar, Abelardo Silva‐Júnior, Alain Kohl et al. · 2022 · ACS Infectious Diseases
61. Waning of IgG, Total and Neutralizing Antibodies 6 Months Post-Vaccination with BNT162b2 in Healthcare Workers
    Jean‐Louis Bayart, Jonathan Douxfils, Constant Gillot, Clara David, François Mullier, Marc Elsen, Christine Eucher, Sandrine Van Eeckhoudt, Tatiana Roy, Vincent Gérin et al. · 2021 · Vaccines
62. COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2·57 million people in Scotland (EAVE II): a prospective cohort study
    Utkarsh Agrawal, Srinivasa Vittal Katikireddi, Colin McCowan, Rachel H Mulholland, Amaya Azcoaga-Lorenzo, Sarah Amele, Adeniyi Francis Fagbamigbe, Eleftheria Vasileiou, Zoe Grange, Ting Shi et al. · 2021 · The Lancet Respiratory Medicine
63. A global database of COVID-19 vaccinations
    Edouard Mathieu, Hannah Ritchie, Esteban Ortiz-Ospina, Max Roser, Joe Hasell, Cameron Appel, Charlie Giattino · 2021 · medRxiv
64. Effectiveness of the Pfizer-BioNTech COVID-19 Vaccine Among Residents of Two Skilled Nursing Facilities Experiencing COVID-19 Outbreaks — Connecticut, December 2020–February 2021
    Britton, Amadea, Jacobs Slifka, Kara M., Edens, Chris, Nanduri, Srinivas Acharya, Bart, Stephen M., Shang, Nong, Harizaj, Adora, Armstrong, Jillian, Xu, Kerui, Ehrlich, Hanna Y. et al. · 2021 · MMWR. Morbidity and Mortality Weekly Report
65. Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil
    Katikireddi, Srinivasa Vittal, Cerqueira-Silva, Thiago, Vasileiou, Eleftheria, Robertson, Chris, Amele, Sarah, Pan, Jiafeng, Taylor, Bob, Boaventura, Viviane, Werneck, Guilherme Loureiro, Flores-Ortiz, Renzo et al. · 2022 · The Lancet
66. Controlling the pandemic during the SARS-CoV-2 vaccination rollout
    João Viana, Christiaan Hendrik van Dorp, Ana Nunes, Manuel C. Gomes, Michiel van Boven, Mirjam Kretzschmar, Marc Veldhoen, Ganna Rozhnova · 2021 · Nature Communications
67. A Systematic Review of Coronavirus Disease 2019 Vaccine Efficacy and Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Disease
    Melissa M. Higdon, Brian Wahl, Carli B. Jones, Joseph G. Rosen, Shaun Truelove, Anurima Baidya, Anjalika Nande, Parisa A ShamaeiZadeh, Karoline K Walter, Daniel R. Feikin et al. · 2022 · Open Forum Infectious Diseases
68. mRNA vaccination of naive and COVID-19-recovered individuals elicits potent memory B cells that recognize SARS-CoV-2 variants
    Aurélien Sokal, Giovanna Barba Spaeth, Ignacio Fernández, Matteo Broketa, Imane Azzaoui, Andréa de La Selle, Alexis Vandenberghe, Slim Fourati, Anaïs Roeser, Annalisa Meola et al. · 2021 · Immunity
69. Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study
    Catherine J. Hyams, Robin D. Marlow, Zandile Maseko, Jade King, Lana Ward, Kazminder Fox, Robyn Heath, Anabella Tuner, Zsolt Friedrich, Leigh Morrison et al. · 2021 · The Lancet Infectious Diseases
70. Antibody responses to BNT162b2 mRNA COVID-19 vaccine and their predictors among healthcare workers in a tertiary referral hospital in Japan
    Takahiro Kageyama, Kei Ikeda, Shigeru Tanaka, Toshibumi Taniguchi, Hidetoshi Igari, Yoshihiro Onouchi, Atsushi Kaneda, Kazuyuki Matsushita, Hideki Hanaoka, Taka‐aki Nakada et al. · 2021 · Clinical Microbiology and Infection
71. Covid‐19 vaccination during the third trimester of pregnancy: rate of vaccination and maternal and neonatal outcomes, a multicentre retrospective cohort study
    Misgav Rottenstreich, Hen Yitzhak Sela, Reut Rotem, Ela Kadish, Yonit Weil‐Weiner, Sorina Grisaru‐Granovsky · 2021 · BJOG An International Journal of Obstetrics & Gynaecology
72. Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination
    Matthew J. Gorman, Nita Patel, Mimi Guebre‐Xabier, Alex Lee Zhu, Caroline G. Atyeo, Krista M. Pullen, Carolin Loos, Yenny Goez-Gazi, Ricardo Carrion, Jing-Hui Tian et al. · 2021 · Cell Reports Medicine
73. Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against SARS-CoV-2 in People Living with HIV (PLWH) Receiving Antiretroviral Therapy (ART) According with Current CD4 T-Lymphocyte Count
    Andrea Antinori, Stefania Cicalini, Silvia Meschi, Veronica Bordoni, Patrizia Lorenzini, Alessandra Vergori, Simone Lanini, Lidya De Pascale, Giulia Matusali, Davide Mariotti et al. · 2021 · Clinical Infectious Diseases
74. Decreases in COVID-19 Cases, Emergency Department Visits, Hospital Admissions, and Deaths Among Older Adults Following the Introduction of COVID-19 Vaccine — United States, September 6, 2020–May 1, 2021
    Athalia Christie, S. Jane Henley, Linda Mattocks, Robyn Fernando, Amy Lansky, Farida B. Ahmad, Jennifer Adjemian, Robert N. Anderson, Alison M. Binder, Kelly Carey et al. · 2021 · MMWR Morbidity and Mortality Weekly Report
75. Delta Variants of SARS-CoV-2 Cause Significantly Increased Vaccine Breakthrough COVID-19 Cases in Houston, Texas
    Paul A. Christensen, Randall J. Olsen, Scott Wesley Long, Sishir Subedi, James J. Davis, Parsa Hodjat, Debbie R. Walley, Jacob C. Kinskey, Matthew Ojeda Saavedra, Layne Pruitt et al. · 2021 · American Journal Of Pathology
76. Causal Inference Methods for Combining Randomized Trials and Observational Studies: A Review
    Bénédicte Colnet, Imke Mayer, Guanhua Chen, Awa Dieng, Ruohong Li, Gael P. Varoquaux, Jean‐Philippe Vert, Julie Josse, Shu Yang · 2024 · Statistical Science
77. Effectiveness of BNT162b2 Vaccine against Omicron in Children 5 to 11 Years
    Sharon Hui Xuan Tan, Alex Richard Cook, Derrick Heng, Benjamin K.C. Ong, David Chien Lye, Kelvin Bryan Tan · 2022 · New England Journal of Medicine
78. Hypermetabolic lymphadenopathy following administration of BNT162b2 mRNA Covid-19 vaccine: incidence assessed by [18F]FDG PET-CT and relevance to study interpretation
    Dan Cohen, Shir Hazut Krauthammer, Ido Wolf, Einat Even‐Sapir · 2021 · European Journal of Nuclear Medicine and Molecular Imaging
79. Increased risk for COVID ‐19 breakthrough infection in fully vaccinated patients with substance use disorders in the United States between December 2020 and August 2021
    Lindsey Wang, QuanQiu Wang, Pamela B. Davis, Nora D. Volkow, Rong Xu · 2021 · World Psychiatry
80. Effectiveness of the BNT162b2 Vaccine after Recovery from Covid-19
    Ariel Hammerman, Ruslan Sergienko, Michael Friger, Tanya Beckenstein, Alon Peretz, Doron Netzer, Shlomit Yaron, Ronen Arbel · 2022 · New England Journal of Medicine
81. Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer–BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study
    Eric J. Haas, John M. McLaughlin, Farid L. Khan, Frederick J. Angulo, Emilia Anis, Marc Lipsitch, Shepherd Roee Singer, Gabriel Mircus, Nati Brooks, Meir Smaja et al. · 2021 · The Lancet Infectious Diseases
82. Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: interim results of a living systematic review, 1 January to 14 May 2021
    Thomas Harder, Judith Koch, Sabine Vygen-Bonnet, Wiebe Külper‐Schiek, Antonia Pilic, Sarah Alicia Reda, Stefan Michael Scholz, Ole Wichmann · 2021 · Eurosurveillance
83. SARS-CoV-2 (Covid-19) vaccines structure, mechanisms and effectiveness: A review
    Hadis Fathizadeh, Saman Afshar, Mahmood Reza Masoudi, Pourya Gholizadeh, Mohammad Asgharzadeh, Khudaverdi Ganbarov, Şükran Köse, Mehdi Yousefi, Hossein Samadi Kafil · 2021 · International Journal of Biological Macromolecules
84. mRNA Vaccines: The Dawn of a New Era of Cancer Immunotherapy
    Zhuoya Deng, Yuying Tian, Jianxun Song, Guangwen An, Penghui Yang · 2022 · Frontiers in Immunology
85. RNA therapeutics: updates and future potential
    Caroline Zhang, Biliang Zhang · 2022 · Science China Life Sciences
86. COVID-19 optimal vaccination policies: A modeling study on efficacy, natural and vaccine-induced immunity responses
    Manuel Adrian Acuña‐Zegarra, Saúl Díaz‐Infante, David Baca-Carrasco, Daniel Olmos‐Liceaga · 2021 · Mathematical Biosciences
87. SARS-CoV-2 vaccines: Lights and shadows
    Fabio Angeli, Antonio Spanevello, Gianpaolo Reboldi, Dina Visca, Paolo Verdecchia · 2021 · European Journal of Internal Medicine
88. Emerging SARS-CoV-2 Variants of Concern (VOCs): An Impending Global Crisis
    Angel Yun-Kuan Thye, Jodi Woan‐Fei Law, Priyia Pusparajah, Vengadesh Letchumanan, Kok‐Gan Chan, Learn−Han Lee · 2021 · Biomedicines
89. Glucagon-Like Peptide-1 Receptor Agonists and Pancreatic Cancer Risk in Patients With Type 2 Diabetes
    Dankner, Rachel, Murad, Havi, Agay, Nirit, Olmer, Liraz, Freedman, Laurence S. · 2024 · JAMA Network Open
90. A look into the future of the COVID-19 pandemic in Europe: an expert consultation [viewpoint].
    Emil N. Iftekhar, Viola Priesemann, Rudi Balling, Simon Bauer, Philippe Beutels, André Sergej Calero Valdez, Sarah Cuschieri, Thomas Czypionka, Uga Dumpis, Enrico Glaab et al. · 2021 · BORIS (University Library Bern)
91. Safety and Efficacy of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Different Vaccines at Phase 3
    Yujing Fan, Kwok‐Hung Chan, Ivan Fan‐Ngai Hung · 2021 · Vaccines
92. Maternal-neonatal transfer of SARS-CoV-2 immunoglobulin G antibodies among parturient women treated with BNT162b2 messenger RNA vaccine during pregnancy
    Omer Nir, Anat Schwartz, Shlomi Toussia‐Cohen, Leah Leibovitch, Tzipi Strauss, Keren Asraf, Ram Doolman, Sivan Sharabi, Carmit Cohen, Yaniv Lustig et al. · 2021 · American Journal of Obstetrics & Gynecology MFM
93. Concerns about SARS-CoV-2 evolution should not hold back efforts to expand vaccination
    Sarah E. Cobey, Daniel B. Larremore, Yonatan H. Grad, Marc Lipsitch · 2021 · Nature reviews. Immunology
94. Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England
    2021
95. Present variants of concern and variants of interest of severe acute respiratory syndrome coronavirus 2: Their significant mutations in S‐glycoprotein, infectivity, re‐infectivity, immune escape and vaccines activity
    Chakraborty, Chiranjib, Bhattacharya, Manojit, Sharma, Ashish Ranjan · 2022 · Reviews in Medical Virology
96. Neurologic adverse events among 704,003 first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine in Mexico: A nationwide descriptive study
    Miguel A Garcia-Grimshaw, Santa Elizabeth Ceballos‐Liceaga, Laura E. Hernández‐Vanegas, Isaac Núñez, Noé Hernández-Valdivia, Daniel Amado Carrillo-García, Anaclara Michel‐Chávez, Javier Andrés Galnares‐Olalde, Guillermo Carbajal‐Sandoval, María del Mar Saniger‐Alba et al. · 2021 · Clinical Immunology
97. Humoral and Cellular Responses to mRNA-1273 and BNT162b2 SARS-CoV-2 Vaccines Administered to Hemodialysis Patients
    José Jesús Broseta, Diana Rodríguez‐Espinosa, Néstor Rodríguez, Mar Mosquera, María Ángeles Marcos, Natalia Egri, Mariona Pascal, Erica Soruco, José Luis Bedini, Beatriu Bayés et al. · 2021 · American Journal of Kidney Diseases
98. Review of Early Immune Response to SARS-CoV-2 Vaccination Among Patients With CKD
    Edward J Carr, Andreas Kronbichler, Matthew P. M. Graham-Brown, Graham E. Abra, Christos Argyropoulos, Lorraine Harper, Edgar V. Lerma, Rita S. Suri, Joel Michels Topf, Michelle Kay Willicombe et al. · 2021 · Kidney International Reports
99. Evidence of SARS-CoV-2-Specific Memory B Cells Six Months After Vaccination With the BNT162b2 mRNA Vaccine
    Annalisa Ciabattini, G Pastore, Fabio Fiorino, Jacopo Polvere, Simone Lucchesi, Elena Pettini, Stefano Auddino, Ilaria Rancan, Miriam Durante, Michele Miscia et al. · 2021 · Frontiers in Immunology
100. mRNA vaccines for COVID-19 and diverse diseases
     Abid Hussain, Haiyin Yang, Mengjie Zhang, Qing Liu, Ghallab Alotaibi, Muhammad Faisal Irfan, Huining He, Jin Keun Chang, Xing‐Jie Liang, Yuhua Weng et al. · 2022 · Journal of Controlled Release